- SID Score
- 5.5/10
- Fair value
- $27.01
- Generated
- Sep 25, 2026
- Model
- claude-haiku-4-5-20251001
Roche Holding AG (RHHBY) trades at $54.44 with a market capitalization of $318.7 billion, positioning it as a major healthcare leader. However, the stock presents a conflicted investment picture, with a current valuation significantly above the fair value estimate of $27.01 (implying 50.1% downside), while analyst consensus maintains a "Hold" rating with an average price target of $57.00. The company's SID Score of 5.5/10 reflects mixed investment quality across multiple dimensions, suggesting caution for new investors despite the company's established market position.
Roche demonstrates solid earnings execution with recent results beating estimates—most notably the H1 2025 EPS of $11.10 versus the $10.94 estimate and H1 2024's $10.23 actual versus $9.34 estimate—indicating operational competence. The P/E ratio of 44.08 appears stretched relative to historical healthcare industry averages and the company's own fair value estimate, suggesting the market has priced in significant future growth expectations. The Factor Grades reveal concerning fundamentals, particularly the "F" rating for Value, while Growth, Profitability, Momentum, and Dividends all receive only "C" marks, indicating the stock lacks compelling attributes across most investment criteria. The minimal dividend yield of 0.03% provides virtually no income component for investors.
Technical analysis data is significantly limited, with moving averages (50-day and 200-day) and the RSI(14) all showing as "N/A," preventing comprehensive trend assessment or momentum evaluation. Without these critical indicators, investors cannot assess whether the stock is overbought, oversold, or trading within established support and resistance levels. The absence of this data constrains confidence in timing entry or exit points and limits the ability to confirm fundamental concerns with technical evidence.
Analyst & Insider Sentiment
The analyst consensus of "Hold" with an average price target of $57.00 suggests limited upside from the current $54.44 price, offering only approximately 4.7% appreciation potential. Insider activity appears minimal, with no meaningful share purchases or sales recorded in recent transactions (all showing 0 shares), which fails to provide conviction regarding management's confidence in the stock's valuation or near-term prospects. The neutral news sentiment further supports a cautious stance, suggesting no catalysts are expected to drive near-term re-rating.
The most significant risk is valuation, with the current price representing an approximate 101% premium to the fair value estimate of $27.01, creating substantial downside exposure if market sentiment shifts or growth expectations normalize. The lack of dividend income (0.03% yield) leaves investors entirely dependent on capital appreciation for returns, increasing portfolio volatility. Additional risks include the limited technical data availability, which hampers risk management, and the "F" rating for value indicating the stock may be vulnerable to mean reversion or market corrections in healthcare equities.
Roche is not recommended as a buy at current levels for value-conscious investors, given the significant valuation premium and fair value estimate suggesting 50% downside risk. The "Hold" consensus and mixed factor grades support a cautious approach, suitable only for existing shareholders or those with a strong conviction in long-term pharmaceutical growth despite current pricing. For new capital allocation, investors should either wait for a materially lower entry point closer to the $27-35 range or consider alternative healthcare holdings with better value characteristics and higher dividend yields.
